Michael Gutch

Mike Gutch, Ph.D. is currently the Chief Financial Officer at Noema Pharma. Prior to Noema Pharma, he served as Chief Business Officer and Chief Financial Officer at Entasis Therapeutics, and before that as Executive Director within AstraZeneca’s Corporate Development group with responsibility for mergers and acquisitions, divestments, and strategic equity investments. Previously, Dr. Gutch had experience as both a corporate and private venture capital investor as a Managing Director of MedImmune Ventures, a Director with H.I.G. BioVentures and a Principal with Lilly Ventures, the corporate venture capital arm of Eli Lilly & Company. While at Eli Lilly, Dr. Gutch was also in the Corporate Financing and Investment Banking group, where he focused on mergers and acquisitions and licensing transactions.

Dr. Gutch earned his Ph.D. in Cellular and Molecular Pathology from the State University of New York at Stony Brook and was a post-doctoral research fellow at both UCSF and the Cold Spring Harbor Laboratories. He earned his M.B.A. in finance from Indiana University. Mike also serves as a member of the Board of Directors for Southeast BIO, a member of the Johns Hopkins Alliance for Science & Technology Development, and a member of the Emory University New Venture Advisory Board.